摘要
目的探讨p53、p16、细胞角蛋白5/6(CK5/6)、血管内皮生长因子(VEGF)和Ki-67在乳腺癌组织中的表达及临床意义。方法采用免疫组化法检测139例乳腺癌及癌旁正常组织中p53、p16、CK5/6、VEGF和Ki-67的表达,分析其与患者临床特征及预后的关系。结果乳腺癌组织中,p53、CK5/6、VEGF和Ki-67的阳性表达率高于癌旁正常组织,p16的阳性表达率低于癌旁正常组织(P<0.05)。p53的表达与TNM分期、组织学分级和淋巴结转移有关(P<0.05);p16、VEGF的表达与病理类型和淋巴结转移有关(P<0.05);CK5/6的表达与年龄、组织学分级和淋巴结转移有关(P<0.05);Ki-67的表达与TNM分期和淋巴结转移有关(P<0.05)。p53、CK5/6、VEGF和Ki-67阳性表达患者的3年总生存率低于阴性表达患者,p16阳性表达患者的3年总生存率高于阴性表达患者(P<0.05)。结论 p53、p16、CK5/6、VEGF和Ki-67的表达与乳腺癌的浸润、转移及预后密切相关,可作为乳腺癌诊断及预后评估的重要指标。
Objective To investigate the expressions and clinical significance of p53,p16,cytokeratin(CK)5/6,vascular endothelial growth factor(VEGF) and Ki-67 in breast cancer tissues.Methods The expressions of p53, p16, CK5/6,VEGF and Ki-67 were detected in breast cancer tissues and tumor-adjacent normal tissues in 139 patients with breast cancer.The relationship of the expressions of p53,p16,CK5/6,VEGF and Ki-67 with the clinical characteristics and prognosis was analyzed.Results The positive expression rates of p53,CK5/6,VEGF and Ki-67 in breast cancer tissues were higher,but p16 expression rate was lower,than those in tumor-adjacent normal tissues(P<0.05).The expression of p53 was closely related with TNM stage,histological grade and lymph node metastasis(P<0.05).The expressions of p16 and VEGF were closely related with pathological type and lymph node metastasis(P<0.05).CK5/6 expression was closely related with age,histological grade and lymph node metastasis(P<0.05).Ki-67 expression was closely related with TNM stage and lymph node metastasis(P<0.05).The 3-year survival rates in the patients with positive expressions of p53,CK5/6,VEGF and Ki-67 were lower than those in the patients with negative expressions(P<0.05).The 3-year survival rate in the patients with positive expression of p16 was higher than that in the patients with negative expression(P<0.05).Conclusion The expressions of p53,p16,CK5/6,VEGF and Ki-67 are closely related to the invasion,metastasis and prognosis of breast cancer,which can be used as the indicators for the diagnosis and prognosis evaluation in the patients with breast cancer.
作者
许立生
王水
赵志泓
王坤
XU Lishen;WANG Shui;ZHAO Zhihong(Department of Thyroid and Breast Surgery, Affiliated Hospital, Jiangsu University, Zhenjiang 212001, CHINA)
出处
《江苏医药》
CAS
2019年第8期770-773,F0002,共5页
Jiangsu Medical Journal
基金
江苏大学附属医院科技项目(jdfyRC2018007)
